Type 2 diabetes: One disease, multiple cardiovascular risk factors

Coronary Artery Disease

Volumn 10, Issue 1, 1999, Pages 23-30

  Calles Escandon, Jorge ^a   Garcia Rubi, Ernesto ^b   Mirza, Shirwan ^b   Mortensen, Aaron ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Diabetes; Insulin resistance; Risk factors; Vascular disease

Indexed keywords

ARTERIOSCLEROSIS; BLOOD CLOTTING; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; BLOOD COAGULATION; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; RISK FACTORS;

EID: 0032617683     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199901000-00004     Document Type: Review

References (101)

1. Webster MW, Scott RS. What cardiologists need to know about diabetes [Review]. Lancet 1997; 350 (suppl 1):S123-S128.
2. Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia 1996; 39:1655-1661.
3. Steiner G. The dyslipoproteinemias of diabetes [Review]. Atherosclerosis 1994; 110 (suppl 2):S27-S33.
4. Steiner G, Lewis GF. Hyperinsulinemia and triglyceride-rich lipoproteins [Review]. Diabetes 1996; 45 (suppl 3):S24-S26
5. Lewis GR Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperlnsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993; 42:833-842.
6. Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertrigtyceridermia and low HDL cholesterol levels. Diabetes 1996; 45 (suppl 3):S27-S30. Excellent review of the tipid abnormalities in diabetes.
7. Lewis GF, Zinman B, Uffelman KD, Szeto L, Weller B, Steiner G. VLDL production is decreased to a simitar extent by acute portal vs. peripheral venous insulin. Am J Physiol 1994; 267 (suppl 1):E566-E572.
8. Orekhov AN, Tertov VV, Smirnov VN. Lipids in cells of atherosclerotic and uninvolved human aorta. II. Lipid metabolism in primary culture. Exp Mol Pathol 1985; 43:187-195.
9. Kim HJ, Kurup IV. Nonenzymatic glycosylation of human plasma low density lipoprotein. Evidence for in vitro and in vivo glucosylation, Metab Clin Exper 1982; 31:348-353.
10. Curtiss LK, Witztum JL. Plasma apolipoproteins Al, All, B, Cl, and E arc glucosylated in hyperglycemic diabetic subjects. Diabetes 1985; 34:452-461.
11. Klein RL, Lopes-Virella MF. Metabolism by human endothelial cells of very low density lipoprolein subfractions isolated from type 1 (insulin-dependent) diabetic patients. Diabetologia 1993; 36:258-264.
12. Lopes-Virella MF, Sherer GK, Lees AM, Wohltmann H, Mayfield R, Sagel J, et al. Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients; changes with metabolic control. Diabetologia 1982; 22:430-436.
13. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elarn R, Steinberg D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 1982; 31:283-291.
14. Orekhov AN, Tertov VV, Sobenin IA, Smirnov VN, Via DP, Guevara K Jr, et al. Sialic acid content of human low density lipoproteins affects their interaction with cell receptors and intracellular lipid accumulation. J Lipid Res 1992; 33:805-817.
15. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985; 34:938-941.
16. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation; pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90:6434-6438.
17. Horiuchi S, Higashi T, Ikeda K, Saishoji T, Jinnouchi Y, Sano H, et al. Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes 1996; 45 (suppl 3):S73-S76.
18. Taniguchi N, Kaneto H, Asahi M, Takahashi M, Wenyi C, Higashiyama S, et al. Involvement of glycation and oxidative stress in diabetic macroangiopathy. Diabetes 1996; 45 (suppl 3):S81-S83.
19. Minick CR, Murphy GE. Experimental induction of atheroarteriosclerosis by the synergy of allergic injury to arteries and lipid-rich diet. II. Effect of repeatedly injected foreign protein in rabbits fed a lipid-rich, cholesterolpoor diet. Am J Pathol 1973; 73:265-300.
20. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MR. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993; 23:95-101.
21. Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MS. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 1988; 168:1041-1059.
22. Lopes-Virella MF, Virella G. Atherosclerosis and autoimmunity [review]. Clin Immunol Immunopathol 1994; 73:155-167.
23. Lopes-Virella MF, Virella G. Cytokines, modified lipoproteins, and arteriosclerosis in diabetes [review]. Diabetes 1996; 45 (suppl 3):S40-S44. A challenging concept in the etiology of atherosclerosis.
24. Winocour PD. Platelet abnormalities in diabetes mollitus [Review]. Diabetes 1992, 41 (suppl 2):26-31.
25. Sharpe PC, Trinick T. Mean platelet volume in diabetes mellitus. Quart J Med 1993; 86:739-742.
26. Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, et al. Evidence for abnormal platelet glycoprotcin expression in diabetes mellitus. Eur J Clin Invest 1990; 20:166-170.
27. Winocour PD. Platelet turnover in advanced diabetes [Review]. Eur J Clin Invest 1994; 24 (suppl 1):34-37.
28. Colwell JA, Winocour PD, Halushka PV. Do platelets have anything to do with diabetic microvascular disease? [Review]. Diabetes 1982; 32 (suppl2):14-19. Of special interest for those with an interest in platelet function and diabetes.
29. Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 1969; 48:1083-1087.
30. Hirsh J, Glynn MF, Mustard JF. The effect of platelet age on platelet adherence to collagen. J Clin Invest 1968; 47:466-473.
31. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury [Review]. Free Rad Biol Med 1990; 9:515-540.
32. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322:1769-1774.
33. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18:399-404.
34. Bastyr E J 3rd, Kadrofske MM, Dershimer RC, Vinik AI. Decreased platelet phosphoinositide turnover and enhanced platelet activation in IDDM. Diabetes 1989; 38:1097-1102.
35. Tschope D, Rosen P, Gries FA. Increase in the cytosolic concentration of calcium in platelets of diabetics type II. Thromb Res 1991; 62:421-428.
36. Watanabe J, Wohltmann HJ, Klein RL, Colwell JA, Lopes-Virella MS. Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes 1988; 37:1652-1657
37. Cohen I, Burk D, Fullerton RJ, Veis A, Green D. Nonenzymatic glycation of human blood platelet proteins. Thromb Res 1989; 55:341-349.
38. Jokl R, Klein RL, Lopes-Virella MF, Colwell JA. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care 1995; 18:1150-1155.
39. Sugimoto H, Franks DJ, Lecavalier L, Chiasson JL, Hamet P. Therapeutic modulation of growth-promoting activity in platelets from diabetics. Diabetes 1987; 36:667-672.
40. Williams E, Timperley WR, Ward JD, Duckworth T, Electron microscopical studies of vessels in diabetic peripheral neuropathy. J Clin Pathol 1980; 33:462-470.
41. Farquhar A, MacDonald MK, Ireland JT. The role of fibrin deposition in diabetic glomeruloscterosis: a light, electron and immunofluorescence microscopy study. J Clin Pathol 1972; 25:657-667.
42. Paton RC. Haemostatic changes in diabetic coma. Diabetologia 1981; 21:172-177.
43. Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 1996; 94:2171-2176.
44. Garcia Frade LJ, de la Calle H, Alava I, Navarro JL, Creighton LJ, Gaffney PJ. Diabetes mollitus as a hypercoagulablo state: its relationship with fibrin fragments and vascular damage. Thromb Res 1987; 47:533-540.
45. Landgraf-Leurs MM, Ladik T, Smolka B, Bock T, Schramm W, Spannagl M, et al. Increased thromboplastic potential in diabetes: a multifactorial phenomenon. Klin Wochenschr 1987; 65:600-606.
46. Fernandez-Castaner M, Camps I, Fernandez-Real JM, Domenech P, Martinez-Brotons F. Increased prothrombin fragment 1 + 2 and D-dimer in first-degree relatives of type 2 diabetic patients. Prethrombotic state in relatives of type 2 diabetic patients. Acta Diabetol 1996; 33:118-121.
47. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects [Review]. Diabetologia 1993; 36:1119-1125.
48. Dornan TL, Rhymes IL, Cederholm-Williams SA, Rizza CR, Pepys MB, Bron AJ, et al. Plasma haemostatic factors and diabetic retinopathy. Eur J Clin Invest 1983; 13:231-235.
49. Ford I, Singh TP, Kitchen S, Makris M, Ward JD, Preston FE. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabet Med 1991; 8:322-329.
50. Husted SE, Nielsen HK, Bak JF, Beck-Nielsen H. Antithrombin III activity, von Willebrand factor antigen and platelet function in young diabetic patients treated with multiple insulin injections versus insulin pump treatment. Eur J Clin Invest 1989; 19:90-94.
51. Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L, et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995; 44:924-928.
52. Brownlee M, Vlassara H, Cerami A. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes. Diabetes 1984; 33:532-535.
53. Mirshahi M, Soria J, Soria C, Bertrand O, Basdevant A. Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen). Thromb Res 1987; 48:279-289.
54. Schernthaner G, Vukovich T, Knobl T, Hay U, Muller MM. The effect of nearnormoglycaemic control on plasma levels of coagulation factor VII and the anticoagulant proteins C and S in insulin dependent diabetic patients. Br J Haematol 1889; 73:356-359.
55. Vukovich TC, Schernthaner G. Decreased protein C levels in patients with insulin-dependent type I diabetes mollitus. Diabetes 1986; 35:617-619.
56. Wilson BD, Pitas RE, Rodgers GM, Regulation of endothellal cell protein C activation by native and oxidised low density lipoprotein. Semin Thromb Hemost 1992; 18:11-17.
57. Ganda OP, Arkin CF. Hyperfibrinogenemia, An important risk factor for vascular complications in diabetes. Diabetes Care 1992; 15:1245-1250.
58. McMillan DE. Plasma protein changes, blood viscosity, and diabetic microangiopathy. Diabetes 1976; 25:858-864.
59. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis [Review]. Diabetologia 1991; 34:457-462.
60. Gray RP, Yudkin JS, Patterson DL. Plasminogen activator inhibitor: a risk lactor for myocardial infarction in diabetic patients. Br Heart J 1993; 69:228-232.
61. Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 1993; 70:530-536.
62. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46:860-867.
63. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocollular cell line Hop G2. Thromb Haemost 1988; 60:491-494.
64. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med 1996; 2:800-803.
65. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13:162-169.
66. Callos-Escandon J, Ballor D, Harvey-Benno J, Ades P, Tracy R, Sobel BE. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr 1996; 64:7-11.
67. Eliasson M, Jansson JH, Nilsson P, Asplund K. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. J Hypertens 1997; 15:349-356.
68. Lemne C, de Faire U. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest 1996; 26:692-697.
69. DeSouza CA, Dengel DR, Rogers MA, Cox K, Macko RF. The fibrinolytic system is not impaired in older men with hypertension. Hypertension 1996; 27:1053-1058.
70. Nordby G, Haaland A, Os I. Evidence of decreased fibrinolytic activity in hypertensive premenopausal women. Scand J Clin Lab Invest 1992; 52:275-281.
71. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227:273-278.
72. Jeng JR, Sheu WH, Jeng CY, Huang SH, Shieh SM. Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996; 9:484-490.
73. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996; 45:623-629.
74. Ehrmann DA, Schneider DJ, Sobol BE, Cavaghan MK, Imperial K, Rosenfield RL, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108-2116.
75. Gray RP, Panahloo A, Mohamed-Ali V, Fatterson DL, Yudkin JS. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial Infarction. Atherosclerosis 1997; 130:171-178
76. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aittaud MF, et al. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete et Metabolisme 1987; 13:331-336.
77. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metab Clin Exper 1986; 35:250-253.
78. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 1991; 88:9959-9963. [published erratum appears in Proc Natl Acad Sci USA 1992; 89:1148].
79. Nordt TK, Sawa H, Fujii S, Sobel BE, Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91:764-770.
80. Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992; 41:890-895.
81. Kooistra T, Bosma PJ, Tons HA, van den Berg AP, Meyor P, Princen HM. Plasminogen activator inhibitor 1 : biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62:723-728.
82. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994; 89:321-330.
83. Cagliero E, Roth T, Roy S, Maiello M, Lorenzi M. Expression of genes related to the extracellular matrix in human endothelial cells. Differential modulation by elevated glucose concentrations, phorbol esters, and cAMP. J Biol Chem 1991; 266:14244-14250.
84. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn, L, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogon activator inhibitor-1. Metab Clin Exper 1990; 39:1044-1048.
85. Mussoni L, Mannucci L, Sirtori M, Camera M, Madorna P, Sironi L, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12:19-27.
86. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9:263-268.
87. Grant PJ, Kruilhof EK, Felley CP, Felber JP, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibilor-1 concentrations in man. Clin Sci 1990; 79:513-516.
88. Vuorinen-Markkola H, Puhakainen I, Yki-Jarvinen H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost 1992; 67:117-120.
89. Calles-Escandon J, Mirza S, Sobel BE, Schneider DJ, Induction of hyperinsulinemia combined with hyperglycemia and hypertriglycerldomla increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998; 47:290-293.
90. Galajda P, Martinka E, Mokan M, Kubisz P. Endothelial markers in diabetes mollitus. Thromb Res 1997; 85:63-65.
91. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Allan C. Fat distribution and plasminogon activator inhibitor activity in nondiabetic obese women. Metab Clin Exper 1989; 38:913-915.
92. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079.
93. Morgensen CE. Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification. Am J Cardiol 1998; 82:4R-8R.
94. Rocchini AP. Insulin resistance and blood pressure regulation in obese and nonobese subjects. Special lecture. Hypertension 1991; 17:837-842.
95. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94:2511-2515. Excellent review of the vasodilatory effect of insulin.
96. Baron AD, Steinberg HO. Endothelial function, insulin sensitivity, and hypertension. Circulation 1997; 96:725-726.
97. Morgensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy British trial shows clear effects of treatment, especially blood pressure reduction. BMJ 1998; 317:693-694.
98. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 1998; 82:9R-14R.
99. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-865.
100. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-853.
101. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.